| Identification | Back Directory | [Name]
RO4929097 | [CAS]
847925-91-1 | [Synonyms]
CS-14
RG-4733
Ro492097
RO4929097
RO4929097, >=98%
RO4929097 (RG-4733)
RO-4929097;RO 4929097
RO4929097;RO-4929097;RO 4929097
RO 4929097, 98%, a γ secretase inhibitor
N1-[(7S)-6,7-Dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropr
N1-[(7S)-6,7-Dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide
Propanediamide, N1-[(7S)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)-
N1-[(7S)-6,7-Dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide Ro 4929097
Ro 4929097 N1-[(7S)-6,7-Dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide | [Molecular Formula]
C22H20F5N3O3 | [MDL Number]
MFCD18384976 | [MOL File]
847925-91-1.mol | [Molecular Weight]
469.4 |
| Chemical Properties | Back Directory | [Boiling point ]
696.3±55.0 °C(Predicted) | [density ]
1.40 | [storage temp. ]
Store at -20°C | [solubility ]
≥23.47 mg/mL in DMSO; insoluble in H2O; ≥45.2 mg/mL in EtOH with ultrasonic | [form ]
solid | [pka]
12.35±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Ro 4929097 acts as a γ-secretase inhibitor used in the treatment of those suffering from solid tumors. It is used to treat pancreatic adenocarcinoma. | [Definition]
ChEBI: A member of the class of dibenzoazepines that is the amide formed from formal condensation of the carboxy group of 2,2-dimethyl-3-oxo-3-[(2,2,3,3,3-pentafluoropropyl)amino]propanoic acid with the amino group of (7S)-7-amino-5,7-dihydrodibe
zo[b,d]azepin-6-one. | [Biological Activity]
ro4929097 is a small-molecule inhibitor of γ secretase with ic50 of 4 nm and ec50 of 5 nm [1]. it shows no in vitro inhibitory activity on the closely related proteases. it also has greater than 100-fold selectivity with respect to 75 other proteins of various types [1]. ro4929097 binds to γ secretase and inhibits its protease activity, therefore blocking the cleavage of notch and reducing notch signaling. up-regulaton of this signaling pathway promotes tumorigenesis of multiple cancers.ro4929097 has shown potential antitumor activity both in vitro and in vivo. it impaired the growth of melanoma cell lines and tumor formation of human primary melanoma xenograft [2]. it slowed proliferation and reduces colony formation of breast cancer cell lines[1]. in addition, ro4929097 decreased tumor formation in xenograft models of colorectal, pancreatic, lung cancer and melanoma[1, 2]. ro4929097 has been tested in multiple phase i/ii | [target]
γ secretase | [storage]
Store at -20°C | [References]
1. luistro l, he w, smith m et al. preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. cancer res 2009; 69: 7672-7680. 2. huynh c, poliseno l, segura mf et al. the novel gamma secretase inhibitor ro4929097 reduces the tumor initiating potential of melanoma. plos one 2011; 6: e25264. 3. richter s, bedard pl, chen ex et al. a phase i study of the oral gamma secretase inhibitor r04929097 in combination with gemcitabine in patients with advanced solid tumors (phl-078/ctep 8575). invest new drugs 2014; 32: 243-249. 4. sahebjam s, bedard pl, castonguay v et al. a phase i study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (pjc-004/nci 8503). br j cancer 2013; 109: 943-949. 5. diaz-padilla i, hirte h, oza am et al. a phase ib combination study of ro4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. invest new drugs 2013; 31: 1182-1191. 6. tolcher aw, messersmith wa, mikulski sm et al. phase i study of ro4929097, a gamma secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. j clin oncol 2012; 30: 2348-2353. 7. strosberg jr, yeatman t, weber j et al. a phase ii study of ro4929097 in metastatic colorectal cancer. eur j cancer 2012; 48: 997-1003. 8. kolb ea, gorlick r, keir st et al. initial testing (stage 1) by the pediatric preclinical testing program of ro4929097, a gamma-secretase inhibitor targeting notch signaling. pediatr blood cancer 2012; 58: 815-818. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.is0513.com/ShowSupplierProductsList15748/0.htm |
|